Avantax Advisory Services Inc. Decreases Stock Holdings in ARK Genomic Revolution ETF (BATS:ARKG)

Avantax Advisory Services Inc. reduced its position in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 33.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,147 shares of the company’s stock after selling 9,554 shares during the period. Avantax Advisory Services Inc.’s holdings in ARK Genomic Revolution ETF were worth $397,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. NBC Securities Inc. increased its stake in shares of ARK Genomic Revolution ETF by 137,400.0% during the first quarter. NBC Securities Inc. now owns 1,375 shares of the company’s stock valued at $28,000 after buying an additional 1,374 shares during the period. BNP Paribas bought a new stake in ARK Genomic Revolution ETF in the fourth quarter valued at $47,000. Capital A Wealth Management LLC purchased a new position in ARK Genomic Revolution ETF during the 4th quarter valued at $60,000. Valley National Advisers Inc. bought a new position in ARK Genomic Revolution ETF in the 1st quarter worth $132,000. Finally, Zuckerman Investment Group LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the 4th quarter worth about $188,000.

ARK Genomic Revolution ETF Stock Down 2.3%

Shares of ARKG opened at $23.07 on Thursday. ARK Genomic Revolution ETF has a 1-year low of $17.51 and a 1-year high of $31.16. The firm’s 50-day moving average price is $24.24 and its 200-day moving average price is $23.62.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.